Kayne Anderson Rudnick Investment Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.26M Sell
8,039
-851
-10% -$128K ﹤0.01% 390
2026
Q1
$1.36M Buy
8,890
+116
+1% +$17.8K ﹤0.01% 353
2025
Q4
$1.21M Sell
8,774
-278
-3% -$36.4K ﹤0.01% 367
2025
Q3
$1.16M Sell
9,052
-28
-0.3% -$3.42K ﹤0.01% 369
2025
Q2
$1.1M Buy
9,080
+55
+0.6% +$6.2K ﹤0.01% 377
2025
Q1
$1.01M Sell
9,025
-485
-5% -$51.6K ﹤0.01% 382
2024
Q4
$925K Sell
9,510
-390
-4% -$41.6K ﹤0.01% 390
2024
Q3
$1.14M Sell
9,900
-325
-3% -$36.9K ﹤0.01% 379
2024
Q2
$1.09M Sell
10,225
-369
-3% -$37K ﹤0.01% 388
2024
Q1
$1.02M Sell
10,594
-669
-6% -$68.6K ﹤0.01% 363
2023
Q4
$1.14M Sell
11,263
-2,795
-20% -$270K ﹤0.01% 357
2023
Q3
$1.43M Sell
14,058
-1,901
-12% -$193K ﹤0.01% 353
2023
Q2
$1.61M Buy
15,959
+469
+3% +$46.9K ﹤0.01% 344
2023
Q1
$1.43M Sell
15,490
-329
-2% -$28.7K ﹤0.01% 339
2022
Q4
$1.44M Buy
15,819
+1,399
+10% +$118K ﹤0.01% 343
2022
Q3
$1.1M Sell
14,420
-885
-6% -$73.4K ﹤0.01% 346
2022
Q2
$1.29M Buy
15,305
+427
+3% +$37.5K ﹤0.01% 332
2022
Q1
$1.31M Sell
14,878
-212
-1% -$18.4K ﹤0.01% 328
2021
Q4
$1.32M Sell
15,090
-849
-5% -$70.5K ﹤0.01% 334
2021
Q3
$1.3M Buy
15,939
+433
+3% +$39K ﹤0.01% 319
2021
Q2
$1.42M Sell
15,506
-119
-0.8% -$10.6K ﹤0.01% 314
2021
Q1
$1.34M Sell
15,625
-857
-5% -$76.9K ﹤0.01% 308
2020
Q4
$1.56M Sell
16,482
-468
-3% -$40.9K ﹤0.01% 303
2020
Q3
$1.47M Buy
16,950
+2,047
+14% +$177K 0.01% 292
2020
Q2
$1.3M Sell
14,903
-4,300
-22% -$371K 0.01% 296
2020
Q1
$1.58M Sell
19,203
-3,061
-14% -$273K 0.01% 271
2019
Q4
$2.11M Buy
22,264
+104
+0.5% +$9.33K 0.01% 273
2019
Q3
$1.93M Sell
22,160
-6,728
-23% -$604K 0.01% 270
2019
Q2
$2.64M Sell
28,888
-433
-1% -$36.6K 0.01% 251
2019
Q1
$2.53M Sell
29,321
-3,922
-12% -$315K 0.01% 234
2018
Q4
$2.56M Sell
33,243
-2,433
-7% -$189K 0.02% 245
2018
Q3
$2.75M Buy
35,676
+407
+1% +$30.1K 0.02% 235
2018
Q2
$2.39M Sell
35,269
-1,851
-5% -$128K 0.02% 241
2018
Q1
$2.69M Buy
37,120
+3,919
+12% +$298K 0.02% 225
2017
Q4
$2.5M Buy
33,201
+1,880
+6% +$142K 0.02% 242
2017
Q3
$2.41M Buy
31,321
+34
+0.1% +$2.57K 0.02% 240
2017
Q2
$2.34M Buy
31,287
+23
+0.1% +$1.63K 0.02% 238
2017
Q1
$2.08M Buy
31,264
+1,737
+6% +$116K 0.02% 254
2016
Q4
$1.93M Sell
29,527
-1,752
-6% -$114K 0.02% 258
2016
Q3
$2.21M Buy
31,279
+197
+0.6% +$14.4K 0.03% 241
2016
Q2
$2.3M Buy
31,082
+7,562
+32% +$522K 0.03% 224
2016
Q1
$1.53M Sell
23,520
-8,894
-27% -$605K 0.02% 246
2015
Q4
$2.5M Sell
32,414
-4,230
-12% -$336K 0.04% 205
2015
Q3
$3.02M Sell
36,644
-7,284
-17% -$648K 0.05% 189
2015
Q2
$3.87M Buy
43,928
+1,836
+4% +$168K 0.06% 178
2015
Q1
$3.72M Sell
42,092
-5,428
-11% -$481K 0.06% 178
2014
Q4
$3.95M Buy
47,520
+1,569
+3% +$130K 0.07% 176
2014
Q3
$3.88M Sell
45,951
-159,693
-78% -$12.9M 0.07% 173
2014
Q2
$16.7M Buy
205,644
+3,997
+2% +$314K 0.28% 101
2014
Q1
$15.4M Buy
201,647
+1,804
+0.9% +$131K 0.27% 104
2013
Q4
$14.4M Buy
199,843
+6,861
+4% +$477K 0.24% 108
2013
Q3
$13.3M Sell
192,982
-54
-0% -$3.57K 0.25% 104
2013
Q2
$12.2M Buy
+193,036
New +$12.6M 0.25% 108

Other funds holding NVS

Kayne Anderson Rudnick Investment Management's NVS Position: Q2 2026 in Review

Kayne Anderson Rudnick Investment Management reduced its Novartis (NVS) stake by 9.6% in Q2 2026, selling an estimated $128K and leaving 8,039 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #390.

Kayne Anderson Rudnick Investment Management first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $16.7M in Q2 2014. 1,614 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Kayne Anderson Rudnick Investment Management held 8,039 shares of Novartis worth $1.26M as of Q2 2026.
  • Kayne Anderson Rudnick Investment Management sold 851 Novartis shares in Q2 2026, an estimated $128K.
  • Novartis made up ﹤0.01% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #390 holding.
  • Kayne Anderson Rudnick Investment Management first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Kayne Anderson Rudnick Investment Management's Novartis position peaked at $16.7M in Q2 2014.
  • 1,614 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.